COBRA AND AUXILIUM ANNOUNCE EXTENSION OF AGREEMENT TO MANUFACTURE AA4500 FOR AUXILIUM

Cobra Biomanufacturing Plc (AIM: CBF) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL -- News) jointly announce their agreement for the production and supply of the protein biopharmaceutical AA4500. Under the agreement, Cobra will provide scale up and cGMP manufacturing services and supply of drug for Phase II/III clinical trials. AA4500 is being developed by Auxilium as a potential treatment of Peyronie's Disease and Dupuytren's Disease and has been granted orphan drug status by the FDA.

Yahoo News (http://biz.yahoo.com/prnews/050802/nytu105.html?.v=18)